No definition available.

Name:	ions_CollaborativeArrangementAndLicensingAgreementAbstract
Namespace Prefix:	ions_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

- Definition

The number of drugs currently in clinical development under the collaboration agreement.

+ References

No definition available.

+ Details

Name:	ions_NumberOfDrugsCurrentlyInClinicalDevelopment
Namespace Prefix:	ions_
Data Type:	xbrli:integerItemType
Balance Type:	na
Period Type:	duration

- Definition

The difference between the carrying value and the sale price of an investment. A gain would be recognized when the sale price of the investment is greater than the carrying value of the investment. This element refers to the Gain included in earnings and not to the cash proceeds of the sale.

+ References

No definition available.

+ Details

Name:	us-gaap_GainOnSaleOfInvestments
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Amount of cash inflow from the sale of investments classified as other.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 12
-URI http://asc.fasb.org/extlink&oid=98514028&loc=d3e3179-108585

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 24
-URI http://asc.fasb.org/extlink&oid=98514028&loc=d3e3521-108585

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 26
-URI http://asc.fasb.org/extlink&oid=98514028&loc=d3e3574-108585

+ Details

Name:	us-gaap_ProceedsFromSaleOfOtherInvestments
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 225
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03.1)
-URI http://asc.fasb.org/extlink&oid=63488584&loc=d3e20235-122688

+ Details

Name:	us-gaap_Revenues
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Details

Name:	us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=ions_RegulusTherapeuticsIncMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

Collaborative Arrangements and Licensing Agreements, Regulus Therapeutics Inc. (Details) $ in Thousands	3 Months Ended								12 Months Ended
	Dec. 31, 2017 USD ($)	Sep. 30, 2017 USD ($)	Jun. 30, 2017 USD ($)	Mar. 31, 2017 USD ($)	Dec. 31, 2016 USD ($)	Sep. 30, 2016 USD ($)	Jun. 30, 2016 USD ($)	Mar. 31, 2016 USD ($)	Dec. 31, 2017 USD ($) Drug	Dec. 31, 2016 USD ($)	Dec. 31, 2015 USD ($)
Collaborative Arrangement and Licensing Agreement [Abstract]
Revenue earned	$ 172,299	$ 120,911	$ 104,152	$ 110,304	$ 160,349	$ 110,927	$ 38,470	$ 36,874	$ 507,666	$ 346,620	$ 283,703
Regulus Therapeutics Inc. [Member]
Collaborative Arrangement and Licensing Agreement [Abstract]
Number of drugs currently in development \| Drug									2
Revenue earned									$ 0	0	0
Gain on sale of stock											20,211
Proceeds from sale of stock									$ 2,507	$ 4,467	$ 25,527